Skip Navigation



European Heart Journal Advance Access published online on August 31, 2007
European Heart Journal, doi:10.1093/eurheartj/ehm276
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/19/2299    most recent
ehm276v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schoenhagen, P.
Right arrow Articles by Sipahi, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schoenhagen, P.
Right arrow Articles by Sipahi, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Arterial remodelling: an independent pathophysiological component of atherosclerotic disease progression and regression. Insights from serial pharmacological intervention trials

Paul Schoenhagen1,2,* and Ilke Sipahi2

1 Division of Radiology
2 Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA

* Corresponding author. Tel: +1-216-445-7579. E-mail address: schoenp1@ccf.org

This editorial refers to ‘Effect of perindopril on coronary remodelling: insights from a multicenter, randomized study’ by G.A. Rodriguez-Granillo et al., doi:10.1093/eurheartj/ehm255

The first 10% of the full text of this article appears below.

Rodriguez-Granillo et al.1 report arterial remodelling data from the ‘PERSPECTIVE’ study,2 an imaging substudy of the ‘EUROPA’ study.3 ‘EUROPA’ is a randomized, placebo-controlled, multicentre trial, which demonstrated that the angiotensin-converting enzyme (ACE) inhibitor perindopril reduced adverse clinical events in 12 218 patients with stable coronary artery disease (CAD). The EUROPA investigators suggested that the clinical benefit is related to anti-atherosclerotic effects of ACE inhibitors. However, the ‘PERSPECTIVE’ substudy, which examined the impact of perindopril on atherosclerosis in a subset of 118 patients, found neither an effect on plaque burden assessed by intravascular ultrasound (IVUS) nor an effect on angiographic luminal diameter. The lack of change in these imaging end-points could indicate that the clinical benefit . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study
Gastón A. Rodriguez-Granillo, Sebastiaan de Winter, Nico Bruining, Jurgen M.R. Ligthart, Héctor M. García-García, Marco Valgimigli, Pim J. de Feyter, and on behalf of the EUROPA/PERSPECTIVE Investigators
EHJ 2007 28: 2326-2331. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
J.-C. Tardif
Angiotensin-converting enzyme inhibitors and atherosclerotic plaque: a key role in the cardiovascular protection of patients with coronary artery disease
Eur. Heart J. Suppl., August 1, 2009; 11(suppl_E): E9 - E16.
[Abstract] [Full Text] [PDF]